Odyssey Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Odyssey Therapeutics, Inc. filed its Q1 2026 Form 10-Q, detailing a net loss of $38.3 million and cash reserves of $175.7 million, while advancing its lead drug candidates OD-001 and OD-002.